Sleep apnea is a disorder that interferes with breathing during sleep, reducing quality of life. Symptoms include daytime fatigue, irritability, and difficulty concentrating. If left untreated, it can lead to cardiovascular and neurological complications.

The standard treatment for obstructive sleep apnea is the CPAP (Continuous Positive Airway Pressure) device, which can be uncomfortable and impractical for many patients. This has led to many not receiving adequate treatment.

In this context, an innovative pill, AD109, has been developed and has shown promising results in clinical trials. This medication acts on the neuromuscular mechanisms that cause airway collapse.

Clinical trial results

The phase 3 clinical trial, published in the American Journal of Respiratory an Critical Care Medicine, involved 650 patients in the United States and Canada. The results revealed a significant reduction in breathing pauses and apnea severity in the group receiving AD109 compared to placebo.

Patients taking AD109 experienced a 44% decrease in apnea-hypopnea index compared to 18% in the placebo group. Nearly 42% of participants improved to a lower severity category after 26 weeks of treatment.

Finally, some participants reported side effects such as dry mouth, nausea, and insomnia. The United States Food and Drug Administration (FDA) is evaluating the approval of AD109, scheduled for 2027.

Risk factors for developing sleep apnea

The main risk factors that increase the likelihood of developing sleep apnea (especially obstructive, the most common) are:

Factors related to the body and anatomy

Lifestyle factors

Medical and genetic factors

For central sleep apnea (less common), specific factors include congestive heart failure and opioid/narcotic use.

Many of these factors (weight, smoking, alcohol consumption) are modifiable, which allows the risk to be reduced.